Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis
- 1 July 2000
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 43 (7), 1473-1477
- https://doi.org/10.1002/1529-0131(200007)43:7<1473::aid-anr9>3.0.co;2-n
Abstract
An elevated acute-phase response is associated with increased radiologic damage in rheumatoid arthritis (RA), but development of damage in previously normal joints ("new joint involvement") has not previously been investigated. This study was undertaken to investigate the hypothesis that when there is suppression of disease activity as judged by the C-reactive protein level, new joint involvement is reduced to a greater extent than is progression in already damaged joints ("damaged joint progression"). Three hundred fifty-nine patients with active RA were studied as part of a 5-year randomized, prospective, open-label study of disease-modifying antirheumatic drug therapy. Time-averaged CRP was calculated from samples obtained every 6 months, and patients were divided into groups with CRP values of or =25 mg/liter. Radiographs of the hands and feet were scored by the Larsen method; a damaged joint was defined as one with a score of > or =2. The rank correlation between time-integrated CRP and increase in Larsen score was 0.50; the correlation increased to 0.59 for patients entering the study with disease duration of < or =2 years. The percentage of new joint involvement over 5 years varied markedly with time-integrated CRP, from 7.3% in the CRP or =25 mg/liter group (5.4-fold increase). The percentage of damaged joint progression increased from 26.1% in the CRP or =25 mg/liter group (1.6-fold increase). The results of this study provide further confirmation that high CRP levels over time are associated with greater radiologic progression. Although radiologic progression still occurred in both previously normal and damaged joints despite the presence of normal CRP levels, this consisted of proportionately less new joint involvement compared with damaged joint progression. These findings support the idea that disease-suppressive therapy should be instituted at an early stage in patients with RA, before erosive damage has occurred.Keywords
This publication has 12 references indexed in Scilit:
- A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritisRheumatology, 1998
- Guidelines for the management of rheumatoid arthritisArthritis & Rheumatism, 1996
- The Validity of Surrogate Markers in Rheumatic DiseaseRheumatology, 1993
- Biannual Radiographic Assessments of Hands and Feet in a Three‐Year Prospective Followup of Patients with Early Rheumatoid ArthritisArthritis & Rheumatism, 1992
- Precision of Larsen grading of radiographs in assessing progression of rheumatoid arthritis in individual patients.Annals Of The Rheumatic Diseases, 1990
- Analysis of serial measurements in medical research.BMJ, 1990
- Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue diseases, and chronic inflammatory syndromes.Annals Of The Rheumatic Diseases, 1988
- STIMULATION OF CHONDROCYTE DNA SYNTHESIS BY INTERLEUKIN-1Rheumatology, 1988
- Long term progression of joint damage in rheumatoid arthritis.Annals Of The Rheumatic Diseases, 1986
- Radiographic Evaluation of Rheumatoid Arthritis and Related Conditions by Standard Reference FilmsActa Radiologica. Diagnosis, 1977